The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Published version of a preprint
Abstract
Most colorectal cancers (CRC) are initiated by mutations of APC, leading to increased β-catenin–mediated signaling. However, continued requirement of Wnt/β-catenin signaling for tumor progression in the context of acquired KRAS and other mutations is less well-established. To attenuate Wnt/β-catenin signaling in tumors, we have developed potent and specific small-molecule tankyrase inhibitors, G007-LK and G244-LM, that reduce Wnt/β-catenin signaling by preventing poly(ADP-ribosyl)ation-dependent AXIN degradation, thereby promoting β-catenin destabilization. We show that novel tankyrase inhibitors completely block ligand-driven Wnt/β-catenin signaling in cell culture and display approximately 50% inhibition of APC mutation–driven signaling in most CRC cell lines. It was previously unknown whether the level of AXIN protein stabilization by tankyrase inhibition is sufficient to impact tumor growth in the absence of normal APC activity. Compound G007-LK displays favorable pharmacokinetic properties and inhibits in vivo tumor growth in a subset of APC-mutant CRC xenograft models. In the xenograft model most sensitive to tankyrase inhibitor, COLO-320DM, G007-LK inhibits cell-cycle progression, reduces colony formation, and induces differentiation, suggesting that β-catenin–dependent maintenance of an undifferentiated state may be blocked by tankyrase inhibition. The full potential of the antitumor activity of G007-LK may be limited by intestinal toxicity associated with inhibition of Wnt/β-catenin signaling and cell proliferation in intestinal crypts. These results establish proof-of-concept antitumor efficacy for tankyrase inhibitors in APC-mutant CRC models and uncover potential diagnostic and safety concerns to be overcome as tankyrase inhibitors are advanced into the clinic. Cancer Res; 73(10); 3132–44. ©2013 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In CRC cells, Wnt pathway inhibition has been demonstrated to inhibit cell proliferation, reduce tumor-initiating cell numbers, and impair tumor growth in CRC xenograft models [190,191,192,193].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [190]
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · cited 5×
“Growth of mouse intestinal organoids cultured ex vivo requires exogenously supplied R-spondin (for Wnt/b-catenin signaling amplification) and EGF (29).”
BackgroundMethodInfluentialPaneth cells constitute the niche for Lgr5 stem cells in intestinal crypts
Sato, T., van Es, J. H., Snippert, H. J., Stange, D. E., Vries, R. G., van den Born, M., Barker, N., Shroyer, N. F., van de Wetering, M., & Clevers, H. (2011) · Nature · doi:10.1038/nature09637 · Cited by 2,510 · cited 2×
“In mouse small intestine, ligand-induced Wnt/b-catenin signaling in intestinal stem cells maintains multipotent stem cell self-renewal (8).”
BackgroundCrypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166 · cited 1×
“Mouse Apc deletion specifically in Lgr5þ intestinal stem cells produces neoplasia (7).”
BackgroundTankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Huang, S.-M. A., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009) · Nature · doi:10.1038/nature08356 · Cited by 2,037 · cited 5×
“AXIN1 andAXIN2protein levels are constitutively suppressed through poly(ADP-ribosyl)ation (PARsylation) by tankyrases TNKS1 and TNKS2 (16), which directs AXIN ubiquitylation by RNF146 and proteasomal degradation (17, 18).”
BackgroundInfluentialThe β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
APC mutations occur early during colorectal tumorigenesis
Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. N., Vogelstein, B., & Kinzler, K. W. (1992) · Nature · doi:10.1038/359235a0 · Cited by 1,924 · cited 3×
“Discussion Almost all colorectal tumors carry mutations in APC or b-catenin that lead to activation ofWnt/b-catenin signaling (4, 5), and many CRC cell lines and tumor models maintain a requirement for activated b-catenin signaling for growth (10– 14).”
BackgroundMolecular Genetics of Colorectal Cancer
Fearon, E. R. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130235 · Cited by 1,805
Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer
Chen, B., Dodge, M. E., Tang, W., Lu, J., Ma, Z., Fan, C.-W., Wei, S., Hao, W., Kilgore, J., Williams, N. S., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.137 · Cited by 1,383
A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable
Tian, H., Biehs, B., Warming, S., Leong, K. G., Rangell, L., Klein, O. D., & de Sauvage, F. J. (2011) · Nature · doi:10.1038/nature10408 · Cited by 1,204 · cited 1×
“Interestingly, this effect is reversible (27) and, in fact, complete ablation of Lgr5þ intestinal stem cells can be tolerated without perturbing the long-term homeostasis of the intestine as new Lgr5þ stem cells appear to be generated from another cell population (42, 43).”
Background
Cited by
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Zhan, T., Rindtorff, N., & Boutros, M. (2017) · Oncogene · doi:10.1038/onc.2016.304 · Cited by 2,626
Can we safely target the WNT pathway?
Kahn, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4233 · Cited by 1,034
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Liu, J., Pan, S., Hsieh, M. H., Ng, N., Sun, F., Wang, T., Kasibhatla, S., Schuller, A. G., Li, A. G., Cheng, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314239110 · Cited by 831
“Pharmacological Wnt inhibitors, such as Tankyrase inhibitors, also recapitulated the gut toxicity at high doses (37, 39).”
BackgroundWnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“Compound G007-LK and G244-LM can damage the proliferation, colony formation, and growth of CRC cells via activating Axins to suppress Wnt/β-catenin signaling.(338) As an adjuvant, G007-LK can also enhance the sensitivity of glioma stem cells to a chemo drug temozolomide and CRC cells to PI3K/EGFR inhibitors.”
Background
Metadata
- Authors
- Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., Machon, O., Korinek, V., Choo, E., Diaz, D., Merchant, M., Polakis, P., Holsworth, D. D., Krauss, S., & Costa, M.
- Affiliations
- Oslo University Hospital (NO)
- Authors' Affiliations: Departments of 1Cancer Targets, 2Translational Oncology, 3Drug Metabolism and Pharmacokinetics, 4Biochemical and Cellular Pharmacology, 5Discovery Chemistry, 6Pharmaceutical Sciences, 7Safety Assessment, and 8Pathology, Genentech, Inc., South San Francisco, California; 9SFI-CAST Biomedical Innovation Center, Unit for Cell Signaling, Oslo University Hospital, Forskningsparken; 10ODIN Therapeutics AS, Forskningsparken, Oslo, Norway; and 11Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic
- Corresponding author
- Costa, Mike
- ORCID
- Venue
- Cancer Research
- Published
- 2013-05-12
- Volume
- 73
- Issue
- 10
- Pages
- 3132-3144
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2105240743
- Cited by
- 316
- References
- 46
- Citations by year
- 2026: 11 · 2025: 21 · 2024: 13 · 2023: 15 · 2022: 16 · 2021: 39 · 2020: 34 · 2019: 27 · 2018: 23 · 2017: 32 · 2016: 25 · 2015: 28 · 2014: 18 · 2013: 12
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- ASEP (submittedVersion, public-domain)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- tankyrase inhibitors, colorectal cancer, APC mutation, Wnt/β-catenin signaling, poly(ADP-ribosyl)ation, tumor growth inhibition, xenograft models, cell cycle progression, intestinal toxicity, KRAS mutation
- MeSH terms
- Animals, Enzyme Inhibitors, Humans, Mutation, Piperidines, Sulfones, Triazoles, Colorectal Neoplasms, Genes, APC, Spheroids, Cellular, Xenograft Model Antitumor Assays, Tankyrases, Cell Line, Tumor, Cell Proliferation, beta Catenin, Mice, Wnt Signaling Pathway, Axin Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-4562
- The paper
- Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., Machon, O., Korinek, V., Choo, E., Diaz, D., Merchant, M., Polakis, P., Holsworth, D. D., Krauss, S., & Costa, M. (2013). A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-4562
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.